Analysts Issue Forecasts for Delcath Systems Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings per share (EPS) estimate for Delcath Systems to ($0.08), down from a previous estimate of $0.02, while maintaining a "Buy" rating with a price target of $31.00.
• Delcath Systems recently reported Q2 earnings of $0.07 EPS, surpassing the consensus estimate of $0.02 EPS, along with revenue of $24.16 million.
• The stock has an average rating of "Moderate Buy" among analysts, with a consensus target price of $24.50.

Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2025 EPS estimates for Delcath Systems in a research note issued to investors on Thursday, August 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.08) per share for the quarter, down from their previous estimate of $0.02. HC Wainwright currently has a "Buy" rating and a $31.00 target price on the stock. The consensus estimate for Delcath Systems' current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems' Q4 2025 earnings at $0.00 EPS, FY2025 earnings at $0.03 EPS and FY2026 earnings at $0.70 EPS.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.05. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%. The company had revenue of $24.16 million during the quarter, compared to the consensus estimate of $22.84 million.

Several other equities research analysts have also recently commented on DCTH. Wall Street Zen cut shares of Delcath Systems from a "buy" rating to a "hold" rating in a research report on Sunday. Stephens reiterated an "overweight" rating and issued a $25.00 price target on shares of Delcath Systems in a research report on Monday, June 23rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Delcath Systems has a consensus rating of "Moderate Buy" and an average target price of $24.50.

Delcath Systems Stock Performance

Shares of DCTH traded down $0.64 during midday trading on Monday, hitting $10.48. 304,350 shares of the stock traded hands, compared to its average volume of 581,054. Delcath Systems has a 1-year low of $7.36 and a 1-year high of $18.23. The firm has a market capitalization of $366.42 million, a PE ratio of 209.22 and a beta of 0.82. The business's 50 day moving average price is $12.63 and its two-hundred day moving average price is $13.51.

Institutional Trading of Delcath Systems

Several institutional investors and hedge funds have recently bought and sold shares of DCTH. Geode Capital Management LLC raised its holdings in Delcath Systems by 14.7% during the 4th quarter. Geode Capital Management LLC now owns 288,951 shares of the company's stock worth $3,481,000 after buying an additional 37,056 shares during the period. Kennedy Capital Management LLC raised its holdings in Delcath Systems by 89.6% during the 4th quarter. Kennedy Capital Management LLC now owns 258,782 shares of the company's stock worth $3,116,000 after buying an additional 122,318 shares during the period. Barclays PLC raised its holdings in Delcath Systems by 466.3% during the 4th quarter. Barclays PLC now owns 65,006 shares of the company's stock worth $782,000 after buying an additional 53,527 shares during the period. Tower Research Capital LLC TRC raised its holdings in Delcath Systems by 1,161.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 14,694 shares of the company's stock worth $177,000 after buying an additional 13,529 shares during the period. Finally, Vivo Capital LLC raised its holdings in Delcath Systems by 71.4% during the 4th quarter. Vivo Capital LLC now owns 1,708,579 shares of the company's stock worth $20,571,000 after buying an additional 711,574 shares during the period. Institutional investors and hedge funds own 61.12% of the company's stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.